Skip to Main Content

Our Team • Leadership


Peter T. Meinke, PhD Peter T. Meinke, PhD
Sanders Director
In 2018, TDI is thrilled to welcome Dr. Peter T. Meinke as the new Sanders Director. Dr. Meinke is an industry veteran with extensive experience across all stages of drug discovery, from target validation through early clinical development. During his long tenure at Merck, his leadership produced one drug – the NS5A inhibitor, elbasvir, for the treatment of chronic hepatitis C – along with 13 development compounds that have advanced into the clinic in seven distinct therapeutic areas. In 2017, Dr. Meinke received the prestigious ACS Heroes of Chemistry Award in recognition of his contributions to the invention of elbasvir. He is co-author of over 90 peer-reviewed publications and co-inventor on more than 35 patents. Dr. Meinke also has significant international leadership experience: from 2008 to 2016, he worked and lived overseas in Shanghai, China, where he directed and mentored global drug discovery research teams while managing attendant business issues.


Current Members

Augustine M.K. Choi, MDAugustine M.K. Choi, MD
Dean, Weill Cornell Medicine
Interim Provost for Medical Affairs, Cornell University
Weill Chairman, Joan and Sanford I. Weill Department of Medicine

Barry Coller, MDBarry Coller, MD
David Rockefeller Professor
The Rockefeller University

Nathaniel Heintz, PhDNathaniel Heintz, PhD
James and Marilyn Simons Professor,
Laboratory of Molecular Biology
The Rockefeller University

Barbara L. Hempstead, MDBarbara L. Hempstead, MD
Dean of the Weill Cornell Graduate School of Medical Sciences
Weill Cornell Medicine

Richard P. Lifton, M.D., Ph.D.Richard P. Lifton, MD, PhD
The Rockefeller University

Carl Nathan, MDCarl Nathan, MD
Chairman of Microbiology and Immunology
Weill Cornell Medicine

David Scheinberg, MD, PhDDavid Scheinberg, MD, PhD
Chairman of Molecular Pharmacology and Chemistry Program
Memorial Sloan Kettering Cancer Center

David Scheinberg, MD, PhDDerek Tan, PhD
Chair, Chemical Biology Program
Sloan Kettering Institute
Memorial Sloan Kettering Cancer Center

Craig B. Thompson, MDCraig B. Thompson, MD
President and CEO
Memorial Sloan Kettering Cancer Center



LaLaurie Glimcher, MDLaurie H. Glimcher, MD
President of Dana-Farber Cancer Institute

Marc Tessier-Lavigne, PhDMarc Tessier-Lavigne, PhD
Stanford University

Tri-I TDI Small Molecule Scientific Advisory Board

Mark Murcko, PhD
Founder & Board Member, Relay Therapeutics
Senior Lecturer, MIT

Mark Duggan, PhD
President, LifeSci Consulting, LLC
Vice President, Neuroscience, AstraZeneca

Joseph Vacca, PhD
President, Vacca Consulting, LLC

Takeda Members

Steven Hitchcock, PhD
Global Research Head
Takeda Pharmaceutical Company

Katherine Galvin, PhD
Sr. Director, Oncology Drug Discovery
Takeda Pharmaceutical Company

Larry Hamann, PhD
Head, Drug Discovery Sciences
Takeda Pharmaceutical Company


Tri-I TDI Antibody Scientific Advisory Board

Matthew Moyle, PhD
CSO, Anaptys Bio, Inc.

Takeda Members

Robert Mabry, PhD
Head of Global Biologics
Takeda Pharmaceutical Company

Natalie D'More, PhD
Director, Oncology
Takeda Pharmaceutical Company

Jill Wykosky, PhD
Sr. Director, Head of Neurogastroenterology
Takeda Pharmaceutical Company



EMERITI - Antibody SAB

Stephen Squinto, PhD
Partner OrbiMed Healthcare Fund Management,
Alexion, Co-Founder and Chef Global Operations Officer

Renier Brentjens, MD, PhD
Medical Oncologist, Director, Cellular Therapeutics
Memorial Sloan Kettering Cancer Center

Paul Chapman, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center

Michel Nussenzweig, MD, PhD
Zanvil A. Cohn and Ralph M. Steinman Professor 
Laboratory of Molecular Immunology
The Rockefeller University

Jeffrey Ravetch, MD, PhD
Theresa and Eugene M. Lang Professor 
Leonard Wagner Laboratory of Molecular Genetics and Immunology
The Rockefeller University

David Artis, PhD
Michael Kors Professor in Immunology
Professor of Immunology in Medicine & Microbiology and Immunology
Weill Cornell Medicine

John Moore, PhD
Professor of Microbiology and Immunology
Weill Cornell Medicine

Joel Scherer, MD
Managing Director and CMO,
Lily Chorus

Paul J. Maddon, PhD
Founder, Progenics Pharmaceuticals, Inc.

David Grayzel, MD
Partner, Atlas Ventures
Arteus Therapeutics, LLC, CEO & Director

Larry Green, PhD
CEO, Ablexis, LLC


EMERITI - Small Molecule SAB

Jim Neidel, PhD
Managing Director, New Leaf Venture Partners
Head of WW R&D, Glaxo Welcome

Nancy Thornberry
Senior Vice President and Franchise Head, Diabetes and Endocrinology
Merck Research Labs

Charles M. Rice, PhD
Maurice R. and Corinne P. Greenberg Professor in Virology
Laboratory of Virology and Infectious Disease
The Rockefeller University

Ari Melnick, MD
Gebroe Family Professor of Hematology/Oncology
Weill Cornell Medicine

James Fagin, MD
Chief, Endocrinology Service
Memorial Sloan Kettering Cancer Center

Neal Rosen, MD
Enid A. Haupt Chair in Medical Oncology
Memorial Sloan Kettering Cancer Center

Derek Tan, PhD
Director, Tri-Institutional Program in Chemical Biology
Memorial Sloan Kettering Cancer Center

Sean Brady, PhD
Investigator, Howard Hughes Medical Institute
Envin Associate Professor, Laboratory of Genetically-encoded Small Molecules
The Rockefeller University

Hermann Steller , PhD
Strang Professor
Strang Laboratory of Apoptosis and Cancer Biology
The Rockefeller University

Paraskevi (Evi) Giannakakou, PhD
Professor of Pharmacology in Medicine
Weill Cornell Medicine

Gregory Petsko, PhD
Arthur J. Mahon Professor of Neurology and Neuroscience
Weill Cornell Medicine

Robert A. Copeland, PhD
Founder, President and CSO
Accent Therapeutics

Kathleen Metters, PhD
President, Black Combe Consulting, Ltd.
Sr. VP External Discovery & Preclinical Sciences, Merck

Laura L. Carter, PhD
Senior Vice President, Biology
Lycera, Inc.

Juan Harrison
Vice President, New Frontier Science
Takeda Pharmaceutical Company


LEADERSHIP Peter T. Meinke, PhDSanders DirectorIn 2018, TDI is thrilled to welcome Dr. Peter T. Meinke as the new Sanders Director. Dr. Meinke is an industry veteran with extensive experience ac